CRIS stock forecast
Our latest prediction for Curis, Inc.'s stock price was made on the Nov. 15, 2017 when the stock price was at 4.95$.
In the short term (2weeks), CRIS's stock price should outperform the market by 5.31%. During that period the price should oscillate between -10.06% and +22.25%.
In the medium term (3months), CRIS's stock price should outperform the market by 3.94%. During that period the price should oscillate between -22.32% and +50.82%.
Get email alertsAbout Curis, Inc.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
At the moment the company generates 11M USD in revenues.
On its last earning announcement, the company reported a loss of -1.03$ per share.
The book value per share is 0.21$
Three months stock forecastNov. 15, 2017
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11M | 94.70% | -31M | -286.39% | -35M | -1.03 | - | - | 33M | 0.21 | -33M | - | -33M |